August 22, 2017 Credit: Martha Sexton/public domain
A type of mouse widely used to assess how the human immune system responds to transplanted stem cells does not reflect what is likely to occur in patients, according to a study by researchers at the Stanford University School of Medicine. The researchers urge further optimization of this animal model before making decisions about whether and when to begin wide-scale stem cell transplants in humans.
Known as "humanized" mice, the animals have been engineered to have a human, rather than a murine, immune system. Researchers have relied upon the animals for decades to study, among other things, the immune response to the transplantation of pancreatic islet cells for diabetes and skin grafts for burn victims.
However, the Stanford researchers found that, unlike what would occur in a human patient, the humanized mice are unable to robustly reject the transplantation of genetically mismatched human stem cells. As a result, they can't be used to study the immunosuppressive drugs that patients will likely require after transplant. The researchers conclude that the humanized mouse model is not suitable for studying the human immune response to transplanted stem cells or cells derived from them.
"In an ideal situation, these humanized mice would reject foreign stem cells just as a human patient would," said Joseph Wu, MD, PhD, director of Stanford's Cardiovascular Institute and professor of cardiovascular medicine and of radiology. "We could then test a variety of immunosuppressive drugs to learn which might work best in patients, or to screen for new drugs that could inhibit this rejection. We can't do that with these animals."
Wu shares senior authorship of the research, which will be published Aug. 22 in Cell Reports, with Dale Greiner, PhD, professor in the Program in Molecular Medicine at the University of Massachusetts Medical School, and Leonard Shultz, PhD, professor at the Jackson Laboratory. Former postdoctoral scholars Nigel Kooreman, MD, and Patricia de Almeida, PhD, and graduate student Jonathan Stack, DVM, share lead authorship of the study.
"Although these mice are fully functional in their immune response to HIV infection or after transplantation of other tissues, they are unable to completely reject the stem cells," said Kooreman. "Understanding why this is, and whether we can overcome this deficiency, is a critical step in advancing stem cell therapies in humans."
"Humanized mice are critical preclinical models in many biomedical fields helping to bring basic science into the clinic, but as this work shows, it is critical to frame the question properly," said Greiner. "Multiple laboratories remain committed to advancing our understanding and enhancing the function of engrafted human immune systems."
Greiner and Shultz helped to pioneer the use of humanized mice in the 1990s to model human diseases and they provided the mice used in the study.
Understanding stem cell transplants
The researchers were studying pluripotent stem cells, which can become any tissue in the body. They tested the animals' immune response to human embryonic stem cells, which are naturally pluripotent, and to induced pluripotent stem cells. Although iPS cells can be made from a patient's own tissues, future clinical applications will likely rely on pre-screened, FDA-approved banks of stem cell-derived products developed for specific clinical situations, such as heart muscle cells to repair tissue damaged by a heart attack, or endothelial cells to stimulate new blood vessel growth. Unlike patient-specific iPS cells, these cells would be reliable and immediately available for clinical use. But because they won't genetically match each patient, it's likely that they would be rejected without giving the recipients immunosuppressive drugs.
Humanized mice were first developed in the 1980s. Researchers genetically engineered the mice to be unable to develop their own immune system. They then used human immune and bone marrow precursor cells to reconstitute the animals' immune system. Over the years subsequent studies have shown that the human immune cells survive better when fragments of the human thymus and liver are also implanted into the animals.
Kooreman and his colleagues found that two varieties of humanized mice were unable to completely reject unrelated human embryonic stem cells or iPS cells, despite the fact that some human immune cells homed to and were active in the transplanted stem cell grafts. In some cases, the cells not only thrived, but grew rapidly to form cancers called teratomas. In contrast, mice with unaltered immune systems quickly dispatched both forms of human pluripotent stem cells.
The researchers obtained similar results when they transplanted endothelial cells derived from the pluripotent stem cells.
A new mouse model
To understand more about what was happening, Kooreman and his colleagues created a new mouse model similar to the humanized mice. Instead of reconstituting the animals' nonexistent immune systems with human cells, however, they used immune and bone marrow cells from a different strain of mice. They then performed the same set of experiments again.
Unlike the humanized mice, these new mice robustly rejected human pluripotent stem cells as well as mouse stem cells from a genetically mismatched strain of mice. In other words, their newly acquired immune systems appeared to be in much better working order.
Although more research needs to be done to identify the cause of the discrepancy between the two types of animals, the researchers speculate it may have something to do with the complexity of the immune system and the need to further optimize the humanized mouse model to perhaps include other types of cells or signaling molecules. In the meantime, they are warning other researchers of potential pitfalls in using this model to screen for immunosuppressive drugs that could be effective after human stem cell transplants.
"Many in the fields of pluripotent stem cell research and regenerative medicine are pushing the use of the humanized mice to study the human immune response," said Kooreman. "But if we start to make claims using this model, assuming that these cells won't be rejected by patients, it could be worrisome. Our work clearly shows that, although there is some human immune cell activity, these animals don't fully reconstitute the human immune system."
The researchers are hopeful that recent advances may overcome some of the current model's limitations.
"The immune system is highly complex and there still remains much we need to learn," said Shultz. "Each roadblock we identify will only serve as a landmark as we navigate the future. Already, we've seen recent improvements in humanized mouse models that foster enhancement of human immune function."
Explore further: Study provides hope for some human stem cell therapies
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Continue reading here:
Mouse model of human immune system inadequate for stem cell ... - Medical Xpress
- COVID-19 Stem Cell Therapies Pipeline, 2020 Report - ResearchAndMarkets.com - Business Wire - May 9th, 2020
- Role of science highlighted in pandemic fight - Chinadaily.com.cn - - May 9th, 2020
- UB investigators uncover cellular mechanism involved in Krabbe disease - UB Now: News and views for UB faculty and staff - University at Buffalo... - May 9th, 2020
- Gilbert Paterson band students to participate in worldwide documentary - Medicine Hat News - May 9th, 2020
- Heard On Sundial: Reopening Miami-Dade And The Keys, And Stem Cell Treatment For Coronavirus - WLRN - May 7th, 2020
- Researchers Convert Astrocytes to Neurons In Vivo to Treat... : Neurology Today - LWW Journals - May 7th, 2020
- Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New Eng - PharmiWeb.com - May 7th, 2020
- BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn for The European Union - GlobeNewswire - May 7th, 2020
- Characterization and Immunomodulation of Canine Amniotic Membrane Stem | SCCAA - Dove Medical Press - May 7th, 2020
- Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy - BioSpace - May 7th, 2020
- Navigating cancer as a young adult: 'I'm trying to figure out who I am' - Stanford Medical Center Report - May 7th, 2020
- Orgenesis leads the charge at an exciting time for cell and gene therapy - Proactive Investors USA & Canada - May 7th, 2020
- DIABETES RESEARCH INSTITUTE FOUNDATION RECEIVES $3 MILLION GIFT FROM NORTH AMERICA'S BUILDING TRADES UNIONS TO FUND CELL THERAPY FOR COVID-19 -... - May 7th, 2020
- End-use Industries of Stem Cell Assay Product Witness Unparalleled Slowdown Induced by Global Outbreak of COVID-361 - 3rd Watch News - May 7th, 2020
- FDA Approves Tabrecta, the First Targeted Drug for Patients with Non-Small Cell Lung Cancer and MET exon 14 - Curetoday.com - May 7th, 2020
- UAE stem cell therapy: Revolutionary treatment helps cure COVID-19 patients - Gulf News - May 3rd, 2020
- Institute for Stem Cell Science and Regenerative Medicine ... - April 29th, 2020
- Scientists from Universities in Russia and Ukraine Collaborate to Research on New Approaches to Treat Obesity and Diabetes - QS WOW News - April 29th, 2020
- Organoids: Exploring Liver Cancer Initiation and the Possibilities of Personalized Glioblastoma Treatment - Technology Networks - April 29th, 2020
- Cell Culture Protein Surface Coating Market Competitive Analysis and Forecast 2017-2025 - Latest Herald - April 29th, 2020
- Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 - BioSpace - April 29th, 2020
- Stem Cell Treatment Options | National Stem Cell Clinic - April 28th, 2020
- Impact of COVID-19 on Stem Cell Assay Market In-Depth Analysis And Forecast 2020-2027 | By Top Key Players Merck & Co., Thermo Fisher Scientific,... - April 28th, 2020
- Dr Annalisa Jenkins on healthcare and biotech investments for family offices - Campden FB - April 28th, 2020
- Researcher says stem cell activation could lie at root of health effects of many natural products - NutraIngredients-usa.com - April 24th, 2020
- Researchers use cell therapy to recover damaged brain areas in mice that suffered - Mirage News - April 24th, 2020
- Scientists explore using CAR-T and other engineered immune cells to target COVID-19 - FierceBiotech - April 24th, 2020
- Lessons for medical profession during management of covid-19 pandemic: Is there a silver lining? - Elets - April 24th, 2020
- Scientists from IKBFU, Moscow and Kiev conducted research on treating obesity - Science Codex - April 24th, 2020
- Outlook on the Worldwide Amniotic Membrane Industry to 2027 - Strategic Recommendations for New Entrants - Yahoo Finance - April 24th, 2020
- Regenerative Medicine Market With Economic Growth And Five Forces Analysis By 2024 - Kentucky Journal 24 - April 21st, 2020
- Northwestern Scientists Awarded Top Honors for Achievement in Clinical Research - Northwestern University NewsCenter - April 17th, 2020
- Campus labs produce sample-preserving fluid for COVID-19 test kits - University of California - April 17th, 2020
- Leading the Movement Towards Direct Cell Conversion: An Interview With Mogrify - Technology Networks - April 17th, 2020
- What exactly are underlying conditions? And why people with them may experience more serious illness from coronavirus - Boston News, Weather, Sports |... - April 17th, 2020
- Pandemic reveals another shortcoming in preparation: Scattershot, chaotic research for treatments - Anchorage Daily News - April 17th, 2020
- Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography - Salamanca Press - April 15th, 2020
- UCSD scientists find possibilities for injured brain cells to be repaired - fox5sandiego.com - April 15th, 2020
- Stem cell therapies slowly gain traction as viable treatments for brain disorders - Science Magazine - April 15th, 2020
- CareDx Introduces AlloCell: Cell Therapy SurveillanceCareDx Announces Collaborations to Develop Cellular Therapy Diagnostics - BioSpace - April 15th, 2020
- NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter - BioSpace - April 15th, 2020
- Leading Urology KOLs Host Live Webinar Entitled The Protect PNS for OAB: A Wireless Uro-Stimulation Injectable Technology on April 29 at 5pm ET -... - April 15th, 2020
- Young-onset Parkinson's may start in the womb - Health24 - April 15th, 2020
- Horizon Research Fellow job with UNIVERSITY OF LEEDS | 203439 - Times Higher Education (THE) - April 15th, 2020
- What You Need to Know About the FDA's Approval of Opdivo-Yervoy for Hepatocellular Carcinoma - Curetoday.com - April 8th, 2020
- MSC-based therapies from Mesoblast, Cynata advance to tackle COVID-19 ARDS - BioWorld Online - April 8th, 2020
- CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19) | DNA RNA and Cells | News... - April 8th, 2020
- AlloVir Appoints Ugo Capolino Perlingieri Head of Europe and Middle East Operations - Yahoo Finance - April 8th, 2020
- What does the public know about COVID-19? - University of Miami - April 8th, 2020
- India Based Stem Cell Research Firm To Test Its Stem Cell Product For Acute Respiratory Disease Syndrome (ARDS) COVID-19 - IndianWeb2.com - April 8th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 Size, Share and Growth Analysis Research Report by 2025. Top Companies are... - April 8th, 2020
- Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies - Xconomy - April 6th, 2020
- Mesoblast's remestemcel-L receives FDA IND clearance for treating COVID-19 patients with acute respiratory distress - Small Caps - April 6th, 2020
- Symtomax: the science behind producing high quality medical cannabis - Health Europa - April 6th, 2020
- Stem Cell Therapy for Colon Cancer - The Ritz Herald - April 6th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Publicist360 - April 6th, 2020
- Dr. Bart Rademaker Offers Free Classes On Stem Cell Therapy And The Coronavirus - PR Web - April 6th, 2020
- BioIVT Opens New Blood Donor Center to Support Boston-area Research into COVID-19 Therapies, Vaccines and Diagnostics - PRNewswire - April 6th, 2020
- Stem Cell Assay Industry - Market Demand | Recent Trends and Developments Analys - News by aeresearch - April 6th, 2020
- GoBroad Healthcare Group Commences Construction of its Research Hospital in Beijing - PRNewswire - March 30th, 2020
- Reviewing CRYO-CELL International (OTCMKTS:CCEL) and Harsco (OTCMKTS:HSC) - Redmond Register - March 29th, 2020
- Study offers potential breakthrough in the war on antibiotic-resistant superbugs - Yahoo Finance - March 26th, 2020
- European Medicines Agency Grants Orphan Drug Designation to AlloVirs Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy -... - March 26th, 2020
- Vitro Biopharma First Quarter ended January 31, 2020 Financial Results of Operations - Benzinga - March 26th, 2020
- Over 65s and vulnerable islanders in Jersey to be put in lockdown - ITV News - March 26th, 2020
- Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer - OrthoSpineNews - March 26th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market : Worldwide Business Analysis and Prediction 2020-2025 || Top Players AVRA Medical... - March 26th, 2020
- The Global Cell Culture Market is expected to grow from USD 14,923.23 Million in 2018 to USD 35,236.23 Million by the end of 2025 at a Compound Annual... - March 25th, 2020
- The Global Cell Isolation/Cell Separation Market is expected to grow from USD 5,721.23 Million in 2018 to USD 15,089.25 Million by the end of 2025 at... - March 25th, 2020
- How Crucial is the Cellular Communications Between the Detached Cancerous Cells and Fibroblast for Growing Metastasis - Spark Health MD - March 25th, 2020
- Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine in Patients with COVID-19 Associated Respiratory Illness - P&T... - March 25th, 2020
- Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position - Seeking Alpha - March 25th, 2020
- AlloVir expands its research collaboration with Baylor College of Medicine | - University Business - March 24th, 2020
- Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights - Yahoo Finance - March 22nd, 2020
- How Skin Cells Prepare To Heal Wounds - Technology Networks - March 22nd, 2020
- Physicians Education Resource to Host Live CME Webcast on COVID-19 and Cancer Care - Yahoo Finance - March 22nd, 2020
- A timely Q&A with Bears tight end and 'resident scientist' Ben Braunecker - The Athletic - March 22nd, 2020
- Immunotherapy using 'young cells' offers promising option against cancer - Washington University School of Medicine in St. Louis - March 21st, 2020
- Stem Cell And Regenerative Therapy Market Research Insights Global Industry Outlook Shared in Detailed Report, Forecast size 2024 - Daily Science - March 21st, 2020
- The personal and economic burden of traumatic brain injury - Eagle & Times - March 21st, 2020